Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with …
SD Nathan, C Albera, WZ Bradford, U Costabel… - Thorax, 2016 - thorax.bmj.com
Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of …
complicated by the variable clinical course. We examined the variability in the rate of …
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
P Rogliani, L Calzetta, F Cavalli, MG Matera… - Pulmonary …, 2016 - Elsevier
Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
A Azuma, Y Taguchi, T Ogura, M Ebina, H Taniguchi… - Respiratory …, 2011 - Springer
Background A phase III trial in Japan showed that pirfenidone is effective for idiopathic
pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we …
pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we …
[HTML][HTML] Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment
S Cerri, M Monari, A Guerrieri, P Donatelli, I Bassi… - Respiratory …, 2019 - Elsevier
Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …